Updates on DNAm: What works to reverse aging from 75 treatments and why a single test might replace the need for all others
DNA methylation based diagnostics have been expanding as a major focus of research and development in the last few years. Now, this research is finally hitting clinical practice in a major way. In this series, we will talk about the most recent updates and why this is important for the ways you manage your clinics and their health.
This will start with an analysis of DNAm clocks for aging. Over the last 5 years, over 2,000 papers have been published on the association of biological age clocks and outcomes. This has reinforced the importance of biological age! Biological age has been clearly identified as the biggest risk factor for all death and chronic disease. We also know that these clocks are some of the most predictive measures of health span as we age.
However, very little has been done to analyze what we can do to reverse these clocks.
In a recent trial done by Yale and TruDiagnostic, over 75 interventional DNAm studies were analyzed with every DNAm clock. In our first presentation, Dr. Mike Stone will discuss the results of this study. We will talk about how interventions such as stem cells, senolytics, growth hormone, hyperbaric oxygen, rapamycin, metformin and more impact these biological age clocks and by how much.
We will also talk about which clocks stood out as the best and how you can use this data to optimize aging in yourself and your patients. This will be the most comprehensive analysis ever done and will give clinicians an appropriate toolkit to improve aging for the patients you work with.
We also will dive into the newest clocks like OMICmAge (created by Harvard) and SymphonyAge (Created by Yale). These clocks can also give resolution on the “why” we age. As people age in different ways, we need resolution for personalized and individual recommendations. The new clocks can do this and we will show that certain interventions can reverse different organ systems’ ages in different ways.
DNA methylation is also a biomarker that extends way beyond aging. Over the past few years, algorithms using DNA methylation data have been developed to predict disease, predict clinical response to common drugs such as metformin and Semaglutide, predict smoking and drinking status, predicting the amount of lead you have been exposed to throughout a lifetime, and these new algorithms have even made diagnosis like schizophrenia and PTSD available with a clear molecular signature.
We will discuss the newest developments here, particularly discussing the new two clinical tests available which can predict your nutritional status of over 80 different biomarkers like Omega-3 status, toxin and pesticide exposure, and more. Dr. Matt Dawson will then explain how these tests are actually even better than most traditional blood based biomarkers.
This conference will be “one of a kind” in providing insights into this rapidly evolving field from both the research and clinical perspective. Any health care provider interested in the newest and most accurate tools to measure aging and many other disease conditions in a single test will not want to miss this conference. The focus of this conference will be on delivering useful information that can be translated into clinical practice and patient education. You will not want to miss this program.
Hourly Schedule
November 19, 2024
- 5:00 pm - 5:30 pm
- Introduction
-
Speakers:
Jeff Bland, PhD
- 5:30 pm - 6:00 pm
- What works to treat aging? The largest, most comprehensive, study on 75 interventions and DNAm Clocks
-
Speakers:
Dr. Mike Stone
- 6:00 pm - 6:30 pm
- Epigenetic Biomarker Proxies, the Future of aging... and literally everything
-
Speakers:
Dr. Matthew Dawson
- 6:30 pm - 7:00 pm
- Panel discussion with all faculty
As CEO of TruDiagnostic, Dr. Dawson oversees a groundbreaking mission to unlock the potential of epigenetic data, empowering individuals and researchers alike to make informed decisions about healthspan and longevity. Under his leadership, TruDiagnostic has become a leader in epigenetic testing and biological aging research, leveraging advanced DNA methylation technology to provide actionable insights into personal health and disease risk.
A passionate advocate for health optimization, Dr. Dawson’s expertise extends beyond traditional medicine, encompassing fitness, nutrition, and biohacking. He is a sought-after speaker, recently contributing to prestigious platforms such as the Personalized Lifestyle Medicine Institute (PLMI), where he is spearheading the integration of Epigenetic Biomarkers (EBPs) and Methylation Risk Scores (MRS) into preventive healthcare strategies. Dr. Dawson's vision for TruDiagnostic focuses on making this emerging science accessible to both clinicians and the general public, driving a future where personalized health interventions are guided by precise epigenetic data.
Speakers
-
Jeff Bland, PhDFunctional Medicine Founder and Pioneer
Dr. Jeffrey Bland is a personable and highly respected thought leader who has spent more than four decades focused on the improvement of human health.
He is known worldwide as the founder of the Functional Medicine movement, which represents his vision for a care model that is grounded in systems biology and informed by research that he has a unique ability to synthesize. His pioneering work has created the Personalized Lifestyle Medicine Institute (PLMI), as well as the Institute for Functional Medicine (IFM), the global leader in Functional Medicine education. Since 1991, hundreds of thousands of healthcare practitioners have participated in PLMI and IFM programs, and this collective knowledge has positively impacted the lives of patients all over the world.
-
Dr. Matthew DawsonCEO, TruDiagnostic
Dr. Matthew Dawson, a leading innovator in the field of epigenetics, is dedicated to bridging cutting-edge genomic science with practical healthcare applications. After earning his medical degree from the University of Kentucky and completing an emergency medicine residency at the University of Utah, where he served as chief resident, Dr. Dawson practiced and taught at the University of Kentucky as an associate professor for seven years. His interest in genomics and epigenetics deepened as he recognized their potential to revolutionize how we understand aging, disease prevention, and human health.
As CEO of TruDiagnostic, Dr. Dawson oversees a groundbreaking mission to unlock the potential of epigenetic data, empowering individuals and researchers alike to make informed decisions about healthspan and longevity. Under his leadership, TruDiagnostic has become a leader in epigenetic testing and biological aging research, leveraging advanced DNA methylation technology to provide actionable insights into personal health and disease risk.
A passionate advocate for health optimization, Dr. Dawson’s expertise extends beyond traditional medicine, encompassing fitness, nutrition, and biohacking. He is a sought-after speaker, recently contributing to prestigious platforms such as the Personalized Lifestyle Medicine Institute (PLMI), where he is spearheading the integration of Epigenetic Biomarkers (EBPs) and Methylation Risk Scores (MRS) into preventive healthcare strategies. Dr. Dawson’s vision for TruDiagnostic focuses on making this emerging science accessible to both clinicians and the general public, driving a future where personalized health interventions are guided by precise epigenetic data. -
Dr. Mike StoneChief Medical Officer , Wild Health
Dr. Mike Stone earned his Bachelor’s degree from Brown University and his MD from NYU School of Medicine, completing his Emergency Medicine residency/fellowship at Alameda Health System/UCSF. He has held academic roles at Harvard Medical School and UCSF, receiving national awards for education, innovation, and leadership.
As Chief Medical Officer and concierge physician at Wild Health, Dr. Stone focuses on lifestyle interventions, precision medicine, and emotional/spiritual alignment to help his patients enhance longevity, cognitive function, performance, connection and life satisfaction.
Sponsor
